Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. (GLUE) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · GLUE · as of Jun 8, 2026
Activity summary
Buy transactions
1
P-Purchase only
Sell transactions
24
12 Months
Buy/Sell ratio
0.04
Buy/Sell (by trades)
Overall sentiment
Monte Rosa Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
GLUE insider buying and selling by quarter
GLUE insider selling · GLUE insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · GLUE ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
GLUE executive sell shares · GLUE board member insider trading · GLUE insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 1, 2026 | Warmuth Markus President & CEO · Director | Sale | 4,998 | $97K | Form 4 |
| Jun 1, 2026 | Warmuth Markus President & CEO · Director | Sale | 468 | $9K | Form 4 |
| May 29, 2026 | Townson Sharon Chief Scientific Officer | Option | 6,000 | $37K | Form 4 |
| May 29, 2026 | Townson Sharon Chief Scientific Officer | Sale | 6,000 | $119K | Form 4 |
| May 27, 2026 | Champoux Jennifer COO | Option | 2,175 | $9K | Form 4 |
| May 27, 2026 | Champoux Jennifer COO | Sale | 2,175 | $44K | Form 4 |
| May 22, 2026 | Champoux Jennifer COO | Option | 2,176 | $9K | Form 4 |
| May 22, 2026 | Champoux Jennifer COO | Sale | 2,176 | $41K | Form 4 |
| May 21, 2026 | Manning Anthony M. Director | Option | 10,000 | $42K | Form 4 |
| May 21, 2026 | Manning Anthony M. Director | Sale | 10,000 | $180K | Form 4 |
| May 1, 2026 | Warmuth Markus President & CEO · Director | Sale | 5,467 | $103K | Form 4 |
| Apr 14, 2026 | Warmuth Markus President & CEO · Director | Sale | 8,000 | $141K | Form 4 |
| Apr 9, 2026 | Nickson Philip Chief Business & Legal Officer | Sale | 5,845 | $103K | Form 4 |
| Apr 6, 2026 | Bowen Matthew PAO | Award | 4,300 | — | Form 4 |
| Mar 4, 2026 | Dunn Edmund PAO | Sale | 139 | $2K | Form 4 |
| Mar 2, 2026 | Warmuth Markus President & CEO · Director | Sale | 5,466 | $98K | Form 4 |
| Feb 27, 2026 | Dunn Edmund PAO | Option | 25,164 | $337K | Form 4 |
| Mar 2, 2026 | Dunn Edmund PAO | Option | 536 | $7K | Form 4 |
| Mar 2, 2026 | Dunn Edmund PAO | Sale | 536 | $9K | Form 4 |
| Feb 27, 2026 | Dunn Edmund PAO | Sale | 25,164 | $456K | Form 4 |
| Feb 23, 2026 | Janku Filip Chief Medical Officer | Sale | 9,189 | $179K | Form 4 |
| Jan 7, 2026 | Warmuth Markus President & CEO · Director | Sale | 3,707 | $86K | Form 4 |
| Jan 7, 2026 | Warmuth Markus President & CEO · Director | Sale | 1,450 | $35K | Form 4 |
| Jan 7, 2026 | Warmuth Markus President & CEO · Director | Sale | 309 | $8K | Form 4 |
| Jan 2, 2026 | Nickson Philip Chief Business & Legal Officer | Award | 28,000 | — | Form 4 |
Warmuth Markus
President & CEO · Director
Date
Jun 1
Shares
4,998
Price
$19.41
Value
$97K
Warmuth Markus
President & CEO · Director
Date
Jun 1
Shares
468
Price
$19.73
Value
$9K
Townson Sharon
Chief Scientific Officer
Date
May 29
Shares
6,000
Price
$6.14
Value
$37K
Townson Sharon
Chief Scientific Officer
Date
May 29
Shares
6,000
Price
$19.87
Value
$119K
Warmuth Markus
President & CEO · Director
Date
May 1
Shares
5,467
Price
$18.92
Value
$103K
Warmuth Markus
President & CEO · Director
Date
Apr 14
Shares
8,000
Price
$17.64
Value
$141K
Nickson Philip
Chief Business & Legal Officer
Date
Apr 9
Shares
5,845
Price
$17.69
Value
$103K
Warmuth Markus
President & CEO · Director
Date
Mar 2
Shares
5,466
Price
$17.92
Value
$98K
Janku Filip
Chief Medical Officer
Date
Feb 23
Shares
9,189
Price
$19.50
Value
$179K
Warmuth Markus
President & CEO · Director
Date
Jan 7
Shares
3,707
Price
$23.24
Value
$86K
Warmuth Markus
President & CEO · Director
Date
Jan 7
Shares
1,450
Price
$23.88
Value
$35K
Warmuth Markus
President & CEO · Director
Date
Jan 7
Shares
309
Price
$24.57
Value
$8K
Nickson Philip
Chief Business & Legal Officer
Date
Jan 2
Shares
28,000
Price
—
Value
—
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About GLUE insider trading
GLUE insider trades
Monte Rosa Therapeutics, Inc. (GLUE) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Warmuth Markus (President & CEO · Director), Champoux Jennifer (COO), Dunn Edmund (PAO). Over the past 12 months, 5 insiders have filed transactions with the SEC. GLUE insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Monte Rosa Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
GLUE insider trading · 5 questionsThe insiders of Monte Rosa Therapeutics, Inc. (GLUE) include executives and directors such as Warmuth Markus (President & CEO · Director), Champoux Jennifer (COO), Dunn Edmund (PAO), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026